In vitro activity of imipenem/relebactam against Gram-negative clinical isolates in two Spanish tertiary hospitals.
Objetive. The aim of this study was to analyze the activity of the imipenem-relebactam combination (IMI/REL) against a collection of multidrug-resist Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii clinical isolates. Material and methods. The study was conducted in two tertiary...
| Publicado en: | Revista Española de Quimioterapia Vol. 34; no. 6; pp. 668 - 672 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artículo |
| Publicado: |
Sociedad Espanola de Quimioterapia
Dec2021
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=154090745&site=ehost-live header: @attributes: shortDbName: lth uiTerm: 154090745 longDbName: MedicLatina uiTag: AN controlInfo: bkinfo: jinfo: jid: 02143429 56RF jtl: Revista Española de Quimioterapia issn: 02143429 maglogo: N pubinfo: dt: Dec2021 vid: 34 iid: 6 pid: 41363 pub: Sociedad Espanola de Quimioterapia artinfo: ui: 154090745 10.37201/req/102.2021 ppf: 668 ppct: 4 formats: fmt: @attributes: type: P size: 259KB tig: atl: In vitro activity of imipenem/relebactam against Gram-negative clinical isolates in two Spanish tertiary hospitals. aug: au: Peñuelas, Marina García-Salguero, Cristina Iñigo, Melania Viñuela-Prieto, Jose Manuel Candel, Francisco Javier del Pozo, José Luis Culebras, Esther affil: Department of Clinical Microbiology, Hospital Clínico San Carlos, IdISCC and IML Health Research Institutes, Complutense University, Madrid, Spain Department of Clinical Microbiology, Clinica Universitaria de Navarra, Campus Madrid, Spain School of Medicine, Complutense University, Madrid, Spain Clinical Microbiology and Infectious Diseases, Hospital Clinico San Carlos, IdISCC and IML Health Research Institutes, Complutense University, Madrid, Spain Clinical Microbiology and Infectious Diseases, Clinica Universitaria de Navarra, Campus Pamplona, Spain su: Imipenem Pseudomonas aeruginosa Acinetobacter baumannii Carbapenems Carbapenemase Beta-lactamase inhibitors sug: subj: Imipenem Pseudomonas aeruginosa Acinetobacter baumannii Carbapenems Carbapenemase Beta-lactamase inhibitors keyword: Carbapenemresistant Enterobacterales Extended-spectrum beta-lactamase Imipenem-relebactam Klebsiella pneumoniae carbapenemase oxacillinase 48 beta-lactamasa de espectro extendido Enterobacteriaceae resistentes a los carbapenémicos Imipenem ab: Objetive. The aim of this study was to analyze the activity of the imipenem-relebactam combination (IMI/REL) against a collection of multidrug-resist Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii clinical isolates. Material and methods. The study was conducted in two tertiary hospitals in Spain and included 192 clinical isolates of these 3 genera (139 resistant and 53 susceptible to IMI). The MICs for IMI with and without REL (at a fixed concentration of 4 mg/L) were determined by a standard broth microdilution method according to international recommendations. Results. All IMI-susceptible E. coli strains were also susceptible to IMI/REL. Enterobacterales resistant to IMI due to the production of carbapenemases, the MIC50 and MIC90 decreased from 64/256 with IMI to 8/64 mg/L with IMI/REL. This high activity was principally detected among isolates with KPC enzymes. Enterobacterales with class B carbapenemases, P. aeruginosa carrying VIM carbapenemase and A. baumannii strains showed no changes on IMI MIC50 or MIC90 after adding REL. Among P. aeruginosa strains without carbapenemase the MIC for IMI/REL was reduced between 1 to 5 dilutions. Conclusions. IMI/REL showed high activity against the strains that carry Klebsiella pneumoniae carbapenemase (KPC) and against carbapenem-resistant P. aeruginosa unrelated to the VIM enzyme, mainly AmpC beta lactamase associated with impermeability. Against strains carrying oxacillinase 48 (OXA- 48) associated with extended-spectrum beta-lactamase (ESBL), IMI/REL presented activity only slightly better than IMI and had no beneficial effect superior to IMI against A. baumannii. Objetivo. El objetivo de este estudio fue analizar la actividad de la combinación imipenem-relebactam (IMI/REL) frente a una colección de aislados clínicos multirresistentes de Enterobacterales, Pseudomonas aeruginosa y Acinetobacter baumannii. Material y métodos. El estudio se realizó en dos hospitales terciarios de España e incluyó 192 aislados clínicos de estos 3 géneros (139 resistentes y 53 susceptibles a IMI). Las CMI para IMI con y sin REL (a una concentración fija de 4 mg/L) se determinaron por un método estándar de microdilución en caldo según las recomendaciones internacionales. Resultados. Todas las cepas de E. coli sensibles a IMI fueron también sensibles a IMI/REL. En el caso de las enterobacterias resistentes a IMI debido a la producción de carbapenemasas, la CMI50 y la CMI90 disminuyeron de 64/256 con IMI a 8/64 con IMI/REL. Esta elevada actividad se detectó principalmente entre los aislados con enzimas KPC. Las enterobacterias con carbapenemasas de clase B, P. aeruginosa portadora de carbapenemasas VIM y las cepas de A. baumannii no mostraron cambios en la CMI50 ni en la CMI90 tras añadir REL. Entre las cepas de P aeruginosa sin carbapenemasas, la CMI para IMI/ REL se redujo entre 1 y 5 diluciones. Conclusiones. IMI/REL mostró una elevada actividad frente a las) y frente a Pseudomonas aeruginosa resistente a carbapenemasas no relacionadas con la enzima VIM, principalmente AmpC beta lactamasa asociada a la impermeabilidad. Contra las cepas portadoras de oxacilinasa 48 (OXA-48) asociadas a betalactamasas de espectro extendido (ESBL), IMI/ cepas portadoras de Klebsiella pneumoniae carbapenemasa (KPC). REL presentó una actividad sólo ligeramente mejor que IMI y no tuvo un efecto beneficioso superior a IMI contra A. baumannii. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: Y custom: Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. item: Revista Española de Quimioterapia holder: Sociedad Espanola de Quimioterapia dt: @attributes: year: 2021 holdings: @attributes: islocal: N |
|---|